AxoGen Company Profile (NASDAQ:AXGN)

Analyst Ratings

Consensus Ratings for AxoGen (NASDAQ:AXGN) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.75 (17.25% upside)

Analysts' Ratings History for AxoGen (NASDAQ:AXGN)
Show:
DateFirmActionRatingPrice TargetActions
5/5/2016WedbushReiterated RatingOutperform$7.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015JMP SecuritiesBoost Price TargetMarket Outperform$5.50 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2015Ladenburg ThalmannDowngradeBuy -> Neutral$5.50 -> $3.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/26/2014Lake Street CapitalInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for AxoGen (NASDAQ:AXGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
8/6/2015($0.14)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015($0.17)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015($0.15)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.20)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014($0.22)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014($0.22)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AxoGen (NASDAQ:AXGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.13)($0.13)($0.13)
Q2 20162($0.13)($0.10)($0.12)
Q3 20162($0.08)($0.08)($0.08)
Q4 20162($0.12)($0.10)($0.11)
Q1 20171($0.05)($0.05)($0.05)
Q2 20171($0.03)($0.03)($0.03)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.00$0.00$0.00
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AxoGen (NASDAQ:AXGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AxoGen (NASDAQ:AXGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/21/2016James E FlynnInsiderSell102,136$6.70$684,311.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2016James E FlynnInsiderSell279,303$7.53$2,103,151.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015James E FlynnInsiderSell345,000$5.50$1,897,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2015Joseph M MandatoDirectorBuy6,500$3.10$20,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Lee Robert Johnston JrInsiderBuy5,000$3.06$15,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2015James E FlynnInsiderSell144,385$3.25$469,251.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Lee Robert Johnston JrCFOBuy10,000$3.06$30,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Mark Stephen GoldDirectorBuy20,000$2.29$45,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2014Mark Stephen GoldDirectorBuy11,000$2.31$25,410.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Lee Robert Johnston JrCFOBuy10,000$2.58$25,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Gregory Gene FreitagCFOBuy5,200$2.45$12,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Karen L ZaderejCEOBuy5,000$2.43$12,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Jill F SchiaparelliSVPBuy2,000$2.63$5,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Karen L ZaderejCEOBuy5,000$2.70$13,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Mark Stephen GoldDirectorBuy1,977$2.60$5,140.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2014Karen L ZaderejCEOBuy1,500$3.49$5,235.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2013Shawn F MccarreySVPBuy25,000$3.21$80,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2013Shawn F MccarreySVPBuy5,000$3.00$15,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Jill F SchiaparelliSVPBuy5,000$3.00$15,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013John Frederick HarperDirectorBuy66,666$3.00$199,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Karen L ZaderejCEOBuy8,334$3.00$25,002.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2012Jill F SchiaparelliSVPBuy2,000$2.55$5,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/29/2012Jill F SchiaparelliSVPBuy1,000$2.70$2,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Jill F SchiaparelliSVPBuy2,750$2.56$7,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2012John Frederick HarperDirectorBuy86,557$3.61$312,470.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AxoGen (NASDAQ:AXGN)
DateHeadline
07/20/16 06:00 AMAxoGen, Inc. to Report Second Quarter Financial Results and Host Conference Call on Wednesday, August 3, 2016 - [GlobeNewswire] - ALACHUA, Fla., July 20, 2016-- AxoGen, Inc., a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter financial ...
07/18/16 07:35 AMAxoGen : Added to Russell 2000® Index
07/06/16 03:31 PMAXOGEN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
06/29/16 10:52 AMAxoGen, Inc. (NASDAQ:AXGN) Company Rating and Target Watch - Telanagana Press
06/29/16 10:52 AMAxoGen, Inc. Added to Russell 2000® Index - GlobeNewswire (press release)
06/29/16 10:52 AMAxoGen, Inc. (NasdaqCM:AXGN) Fundamental Star Rating Report - CML News
06/27/16 06:00 AMAxoGen, Inc. Added to Russell 2000® Index - [GlobeNewswire] - ALACHUA, Fla., June 27, 2016-- AxoGen, Inc., a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that the company has been added to the Russell ...
06/21/16 11:47 AMETF’s with exposure to AxoGen, Inc. : June 21, 2016 -
06/21/16 06:15 AM7:15 am AxoGen announces four presentations related to use of Avance Nerve Graft at the FESSH Congress being held June 22-25 -
06/21/16 06:00 AMAxoGen, Inc.’s Avance® Nerve Graft Data to be Presented at 2016 Federation of European Societies for Surgery of the Hand International Congress - [GlobeNewswire] - ALACHUA, Fla., June 21, 2016-- AxoGen, Inc., a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the acceptance of four presentations at the ...
06/16/16 06:00 AMAxoGen to Present at JMP Securities Healthcare Conference 2016 - [GlobeNewswire] - ALACHUA, Fla., June 16, 2016-- AxoGen, Inc., a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter J. Mariani, Chief Financial Officer, ...
05/31/16 03:41 PMAXOGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securi -
05/26/16 06:14 PMETF’s with exposure to AxoGen, Inc. : May 26, 2016 -
05/13/16 09:21 AMAxoGen, Inc. :AXGN-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/04/16 06:12 PMAxoGen reports 1Q loss -
05/04/16 03:31 PMAxoGen, Inc. First Quarter Revenue Increases 64% Over Prior Year to $8.1 Million - [at noodls] - ALACHUA, Fla., May 04, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results ...
05/04/16 03:09 PMAXOGEN, INC. Files SEC form 10-Q, Quarterly Report -
05/04/16 06:07 AMQ1 2016 AxoGen Inc Earnings Release - After Market Close -
04/29/16 08:52 AMAxoGen (AXGN) Enters Overbought Territory -
04/20/16 07:31 AMAxoGen, Inc. to Report First Quarter Results - [at noodls] - Conference Call Scheduled for Wednesday, May 4, 2016 at 4:30 PM ET ALACHUA, FL - April 20, 2016- AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair ...
04/08/16 05:58 AMAxoGen, Inc. to Feature Nerve Repair Solutions at the American College of Oral and Maxillofacial Surgeons (ACOMS) Annual Scientific Conference and Exhibition - [GlobeNewswire] - ALACHUA, Fla. -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced its participation in the 2016 American ...
03/14/16 06:21 AMKevin Leach Appointed Vice President of Marketing of AxoGen, Inc. - [GlobeNewswire] - ALACHUA, Fla. -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Kevin Leach ...
03/09/16 06:09 AMAxoGen, Inc. to Participate at the 28th Annual ROTH Growth Conference - [GlobeNewswire] - ALACHUA, Fla. -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Karen Zaderej, President and Chief ...
03/01/16 06:04 AMAxoGen Appoints Peter J. Mariani Chief Financial Officer - [GlobeNewswire] - ALACHUA, Fla. -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Peter J. Mariani, ...
02/29/16 07:17 PMAXOGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Offi -
02/29/16 05:44 PMAXOGEN, INC. Files SEC form 10-K, Annual Report -
02/29/16 05:31 PMAxoGen reports 4Q loss -
02/29/16 03:18 PMAxoGen Inc. Reports Record Revenue Results - [GlobeNewswire] - ALACHUA, Fla. -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported record 2015 revenue of $27.33 ...
02/29/16 06:07 AMQ4 2015 AxoGen Inc Earnings Release - After Market Close -
02/26/16 09:30 AMAnalyst Coverage Updates – AxoGen, Inc. (AXGN) - Risers & Fallers - Analyst Coverage Updates – AxoGen, Inc. (AXGN)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of AxoGen, Inc. (AXGN). The latest broker reports which are currently outstanding on Friday 26th of February state 1 analyst has a rating of “strong buy”, 3 analysts “buy”, ...
02/20/16 02:00 PMAxoGen, Inc. (AXGN) Broker Updates - Risers & Fallers - AxoGen, Inc. (AXGN) Broker UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of AxoGen, Inc. (AXGN). According to the latest broker reports outstanding on Friday 19th of February, 1 analyst has a rating of “strong buy”, 3 analysts “buy”, 1 ...
02/15/16 12:41 PMAxoGen, Inc. (NASDAQ:AXGN) Analyst Rating Update - Investor Newswire - AxoGen, Inc. (NASDAQ:AXGN) Analyst Rating UpdateInvestor NewswireWall Street analysts polled by Zacks Research have given AxoGen, Inc. (NASDAQ:AXGN) a rating of 1.5 on a consensus basis. Using a simplified scale where 1 is a Strong Buy and 5 a Strong Sell, this is the average number of the 4 brokerages surveyed.and more »
02/11/16 01:06 PMAxoGen, Inc. to Report Fourth Quarter and Full Year Results on February 29, 2016 - GlobeNewswire (press release) - AxoGen, Inc. to Report Fourth Quarter and Full Year Results on February 29, 2016GlobeNewswire (press release)ALACHUA, Fla., Feb. 10, 2016 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the fourth quarter and full year ended December ...and more »
02/10/16 06:02 AMAxoGen, Inc. to Report Fourth Quarter and Full Year Results on February 29, 2016 - [GlobeNewswire] - ALACHUA, Fla. -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the fourth quarter and full year ended ...
02/06/16 01:15 PMAxoGen, Inc. (NASDAQ:AXGN): Stock in the spotlight - Stocks Daily - AxoGen, Inc. (NASDAQ:AXGN): Stock in the spotlightStocks DailyAxoGen, Inc. (NASDAQ:AXGN) has successfully managed to attain positive rating on its stock. Zacks planned a poll of sell-side experts after which the firm assigned 1.5 rating on company's stock. This consensus rating, which is placed on a 'one to five ...and more »
02/02/16 11:52 AMAxoGen, Inc. (NASDAQ:AXGN): Quarterly Earnings Update - Investor Newswire - AxoGen, Inc. (NASDAQ:AXGN): Quarterly Earnings UpdateInvestor NewswireAs per the research firms that were included in Zacks Research survey, AxoGen, Inc. (NASDAQ:AXGN) is projected an EPS of $-0.04 for last quarter. The firm can release the earnings report on or around 2016-03-03. Since the ratings compiled by Zacks ...and more »
01/27/16 11:09 AMLatest Analysts Reports On AxoGen, Inc. (AXGN) - Risers & Fallers - Latest Analysts Reports On AxoGen, Inc. (AXGN)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of AxoGen, Inc. (AXGN). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 3 analysts “outperform”, 1 analysts “hold”, 0 analysts ...
01/22/16 10:49 AMAxoGen, Inc. (NASDAQ:AXGN) - Stock Sentiment And ABR Update - Investor Newswire - AxoGen, Inc. (NASDAQ:AXGN) - Stock Sentiment And ABR UpdateInvestor NewswireZacks Research has given an average broker rating of 1.5 to AxoGen, Inc. (NASDAQ:AXGN)'s shares. Zacks assigns a simplified score in between one and five against the complex analysts' ratings. A score towards 1-2 typically means a consensus Buy, ...and more »
01/16/16 07:04 PMAxoGen Becomes Oversold (AXGN) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of AxoGen Inc (AXGN) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $4.54 per share. By comparison ...
12/24/15 09:47 AMAxoGen, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/10/15 02:49 PMDo Hedge Funds Love AxoGen, Inc. (AXGN)? -
12/08/15 12:17 PMAXOGEN, INC. Financials -
11/05/15 03:41 PMAxoGen Inc. Third Quarter Revenue Exceeds $8 Million - [at noodls] - - Revenue Increased 74.5%; Gross Profit Margin of 82.7%; AXGN Raises 2015 Guidance ALACHUA, FL - November 5, 2015 - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical ...
11/05/15 03:16 PMAXOGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
11/05/15 06:07 AMQ3 2015 AxoGen Inc Earnings Release - After Market Close -
10/16/15 06:03 AMAxoGen, Inc. to Report Third Quarter Results on November 5, 2015 - [GlobeNewswire] - ALACHUA, Fla. -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter and nine months ended ...
10/08/15 06:14 AMAxoGen, Inc. to Present at the Dawson James Securities Small Cap Growth Conference - [at noodls] - ALACHUA, FL - October 8, 2015 - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is scheduled to present at the Dawson James ...
10/01/15 10:12 AMAxoGen, Inc. Earnings Q2, 2015 -
09/29/15 06:17 AMAxoGen, Inc. to Attend American Association of Oral and Maxillofacial Surgeons (AAOMS) 97th Annual Meeting - [at noodls] - Company to Exhibit Portfolio of Nerve Repair Products at Booth 244 ALACHUA, FL - September 29, 2015 - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for ...
09/16/15 10:21 PMAxoGen Inc.’s Avance® Nerve Graft Data Presented During Best Clinical Papers Session at the 70th Annual Meeting of the American Society for Surgery of the Hand - [at noodls] - AxoGen Inc.’s Avance® Nerve Graft Data Presented During Best Clinical Papers Session at the 70th Annual Meeting of the American Society for Surgery of the Hand

Social

About AxoGen

AxoGen logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AXGN
  • CUSIP:
Key Metrics:
  • Previous Close: $6.64
  • 50 Day Moving Average: $6.53
  • 200 Day Moving Average: $5.57
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $198.86M
  • Beta: 0.41
  • Current Year EPS Consensus Estimate: $-0.43 EPS
  • Next Year EPS Consensus Estimate: $-0.15 EPS
Additional Links:
AxoGen (NASDAQ:AXGN) Chart for Saturday, July, 23, 2016